Skip to main content
. 2015 Jul 27;112(32):9902–9907. doi: 10.1073/pnas.1422401112

Fig. 5.

Fig. 5.

The designed antibody DesAb-F inhibits α-synuclein aggregation. (A) Analysis on the soluble fraction of α-synuclein during its aggregation in the absence (black line) and presence (red line) of 1:10 molar ratio of DesAb-F:α-synuclein. (B) Seeded aggregation assay (3% seeds) at increasing molar ratios of DesAb-F (reported on the right axis). Different replicates for each condition are reported. (C) Initial growth rates over the molar ratios of single domain antibody scaffold. (D) Initial growth rate over the percentage of seeds in the presence of a fixed ratio of antibody (1:5).